BMC Musculoskeletal Disorders

Table 7 Median Percent Changes From Baseline in Selected Lipid Parameters at Month 36^a

From: Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

	Bazedoxifene		Raloxifene	Placebo
Parameter	20 mg	40 mg	60 mg
Total cholesterol
No. of pairs	1220	1201	1225	1248
Median percent change	-3.8^b,c,d	-3.5^b,c,d	-5.0^b,c	0.3
LDL cholesterol
No. of pairs	1220	1201	1223	1247
Median percent change	-5.4^b,c,d	-6.6^b,c,d	-8.5^b,c	1.6^b
HDL cholesterol
No. of pairs	1216	1196	1219	1246
Median percent change	5.1^b,c	5.9^b,c	5.0^b,c	2.5^b
LDL/HDL cholesterol
No. of pairs	1213	1191	1215	1244
Median percent change	-10.5^b,c,d	-12.6^b,c	-12.4^b,c	-0.6
Triglycerides
No. of pairs	1220	1201	1225	1248
Median percent change	8.5^b	13.6^b	12.2^b	12.1^b

LDL, low-density lipoprotein; HDL, high-density lipoprotein.
^aIncludes subjects in the intent-to-treat population (n = 6,847) with an assessment at baseline and at Month 36.
^b P < 0.001 vs baseline; t test.
^c P < 0.001 vs placebo; t test.
^d P < 0.01 vs raloxifene 60 mg; t test.

Back to article page

ISSN: 1471-2474

Contact us

Submission enquiries: bmcmusculoskeletaldisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com